Algburi Ammar R, Jassim Shireen M, Popov Igor V, Weeks Richard, Chikindas Michael L
Department of Microbiology, Veterinary Medicine College, University of Diyala, Baqubah, Iraq.
Alkhalis Section for Primary Care/Thoracic and Respiratory Diseases Unit, Alkhalis, Iraq.
Braz J Microbiol. 2024 Sep;55(3):2581-2592. doi: 10.1007/s42770-024-01363-5. Epub 2024 May 24.
This study aims to evaluate the antibacterial activity of Lactobacillus acidophilus, alone and in combination with ciprofloxacin, against otitis media-associated bacteria. L. acidophilus cells were isolated from Vitalactic B (VB), a commercially available probiotic product containing two lactobacilli species, L. acidophilus and Lactiplantibacillus (formerly Lactobacillus) plantarum. The pathogenic bacterial samples were provided by Al-Shams Medical Laboratory (Baqubah, Iraq). Bacterial identification and antibiotic susceptibility testing for 16 antibiotics were performed using the VITEK2 system. The minimum inhibitory concentration of ciprofloxacin was also determined. The antimicrobial activity of L. acidophilus VB1 cell-free supernatant (La-CFS) was evaluated alone and in combination with ciprofloxacin using a checkerboard assay. Our data showed significant differences in the synergistic activity when La-CFS was combined with ciprofloxacin, in comparison to the use of each compound alone, against Pseudomonas aeruginosa SM17 and Proteus mirabilis SM42. However, an antagonistic effect was observed for the combination against Staphylococcus aureus SM23 and Klebsiella pneumoniae SM9. L. acidophilus VB1 was shown to significantly co-aggregate with the pathogenic bacteria, and the highest co-aggregation percentage was observed after 24 h of incubation. The anti-biofilm activities of CFS and biosurfactant (BS) of L. acidophilus VB1 were evaluated, and we found that the minimum biofilm inhibitory concentration that inhibits 50% of bacterial biofilm (MBIC50) of La-CFS was significantly lower than MBIC50 of La-BS against the tested pathogenic bacterial species. Lactobacillus acidophilus, isolated from Vitane Vitalactic B capsules, demonstrated promising antibacterial and anti-biofilm activities against otitis media pathogens, highlighting its potential as an effective complementary/alternative therapeutic strategy to control bacterial ear infections.
本研究旨在评估嗜酸乳杆菌单独及与环丙沙星联合使用时对中耳炎相关细菌的抗菌活性。嗜酸乳杆菌细胞从Vitalactic B（VB）中分离得到，VB是一种市售益生菌产品，含有嗜酸乳杆菌和植物乳杆菌（原名为植物乳杆菌）两种乳杆菌。致病细菌样本由Al-Shams医学实验室（伊拉克巴古拜）提供。使用VITEK2系统对16种抗生素进行细菌鉴定和药敏试验。还测定了环丙沙星的最低抑菌浓度。使用棋盘法单独及联合环丙沙星评估嗜酸乳杆菌VB1无细胞上清液（La-CFS）的抗菌活性。我们的数据显示，与单独使用每种化合物相比，La-CFS与环丙沙星联合使用时，对铜绿假单胞菌SM17和奇异变形杆菌SM42的协同活性存在显著差异。然而，该组合对金黄色葡萄球菌SM23和肺炎克雷伯菌SM9表现出拮抗作用。结果表明，嗜酸乳杆菌VB1与致病细菌显著共聚集，孵育24小时后观察到最高的共聚集百分比。评估了嗜酸乳杆菌VB1的无细胞上清液（CFS）和生物表面活性剂（BS）的抗生物膜活性，我们发现，La-CFS对受试致病细菌的抑制50%细菌生物膜的最低生物膜抑制浓度（MBIC50）显著低于La-BS的MBIC50。从Vitane Vitalactic B胶囊中分离出的嗜酸乳杆菌对中耳炎病原体表现出有前景的抗菌和抗生物膜活性，突出了其作为控制细菌性耳部感染的有效补充/替代治疗策略的潜力。
